DDInter909 DDInter1676
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Imatinib {u} (Compound) resembles {v} (Compound) Buclizine
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Imatinib {u} (Compound) binds {v} (Gene) CA12
Imatinib {u} (Compound) upregulates {v} (Gene) MEF2C
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
Imatinib {u} (Compound) causes {v} (Side Effect) Eye disorder
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Imatinib (Compound) resembles Buclizine (Compound)
Imatinib (Compound) treats hematologic cancer (Disease)
Imatinib (Compound) binds CA12 (Gene)
Imatinib (Compound) upregulates MEF2C (Gene)
Imatinib (Compound) downregulates DECR1 (Gene)
Imatinib (Compound) causes Eye disorder (Side Effect)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Citalopram
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab